Montpellier, France- May 2024- Cilcare, a clinical-stage biotechnology company specialized in auditory sciences and research and development of novel therapies for the inner ear and associated diseases, is pleased to announce the appointment of Naimi Missoum acting as Chief Medical Officer. A Medical Doctor and clinician with 25+ years of experience as a Medical Affairs Senior Executive in leading pharmaceutical companies, Dr. Missoum will oversee all of Cilcare’s medical initiatives, including clinical development strategies and collaborations with healthcare professionals and regulatory authorities.
A surgeon specialized in ENT disorders, Dr. Missoum worked in hospital settings for over a decade in both surgical interventions and diagnostic practices before transitioning to the pharmaceutical industry. Throughout his career, he held leading roles at prestigious pharmaceutical companies, most recently serving as Global Medical Affairs Executive Director at Biogen, following significant experiences at BMS, MSD China, and Astra Zeneca.
“I am honored to join Cilcare as Chief Medical Officer,” said Mr. Missoum. “I’m passionate about empowering global pharmaceutical projects lead by biotech companies to turn their visions into impactful solutions. Together, I’m convinced we can shape a future of transformative solutions in preventive, predictive, and personalized medicine, making a lasting impact on healthcare. Cilcare is at the forefront of innovation in the field of auditory sciences, and I look forward to contributing to the company’s mission to improve the lives of people with hearing issues and associated disorders.”
Also Read: Rima Alameddine Named President of BD Peripheral Intervention
Furthermore, Cilcare CEO Celia Belline, expressed confidence in Mr. Missoum’s appointment, highlighting his enlightened leadership and ability to inspire the company’s medical team: “Mr. Missoum’s appointment comes at a pivotal moment in Cilcare’s growth as the company is expanding its clinical trial activity. With the launch of a second observational clinical trial in Alzheimer’s and Parkinson’s patients to define the presence of cochlear synaptopathy, and the preparation of Phase 2a for assessing our lead compound, CIL001, in the treatment of this form of hearing impairment, Dr. Missoum’s leadership will be instrumental in driving our mission forward.”
